Papoutsis currently serves as Executive Vice President and Chief Strategy Officer at TerSera Therapeutics. Her background includes the negotiation of more than 30 strategic transactions and the launch of three private equity-backed bioscience startups. At Continuity, she will focus on scaling the company’s partnering activity, a core pillar of its growth strategy as it advances a diverse portfolio of precision drug delivery technologies.
Continuity Biosciences Adds TerSera Executive to Board
Vicky Papoutsis, a veteran strategist with over 25 years of experience in biopharmaceutical development, has joined the Board of Directors at Continuity Biosciences. Her appointment arrives as the Bradenton-based firm transitions from platform development toward clinical execution, specifically targeting its lead pancreatic cancer program.
Robert Whitehead, Co-Founder and Executive Chair of Continuity, noted that the board is being built to bridge the gap between innovation and commercial viability. The company’s pipeline spans oncology, Type 1 diabetes, and HIV prevention, utilizing specialized systems ranging from nanofluidic implants to microneedle delivery. Papoutsis joins a board that includes leaders from UChicago Medicine AdventHealth, Disney Parks and Resorts, and former partners from top-tier regulatory law firms.
Comments (0)
No comments yet. Be the first!